Skip to main content

The independent medical news service

17-02-2021 | Oncology | News | Article

Belzutifan plus cabozantinib shows preliminary activity in metastatic ccRCC

Combination therapy with the HIF-2α inhibitor belzutifan and the multikinase inhibitor cabozantinib shows antitumor activity in people with metastatic clear cell renal cell carcinoma, phase 2 study data show.

16-02-2021 | Oncology | News | Article

Lenvatinib plus pembrolizumab achieve CLEAR survival advantage for clear cell RCC

The CLEAR study has demonstrated a significant progression-free survival gain with use of lenvatinib plus pembrolizumab for the first-line treatment of advanced clear cell renal cell carcinoma.

28-01-2021 | Oncology | News | Article

Baseline variables may predict immunotherapy response in metastatic ccRCC

A number of baseline variables, including age and PD-L1 expression level, may be linked to survival outcomes among people receiving PD-1 or PD-L1 inhibitors for metastatic clear cell renal cell carcinoma, meta-analysis data show.

26-01-2021 | Oncology | News | Article

FDA approves first-line nivolumab–cabozantinib for advanced RCC

Read more about this here

24-12-2020 | Oncology | News | Article

EMA adopts positive opinions for breast, lung, GU cancer indications

Read more about these decisions here

23-10-2020 | Oncology | News | Article

Cabozantinib improves quality-adjusted survival in advanced RCC

Treatment with cabozantinib gives patients with advanced renal cell carcinoma significantly more time without disease progression and toxicity relative to treatment with sunitinib, CABOSUN trial data show.